C12N 15/902
Using homologous recombination
Official title: {using homologous recombination}
C12N15/902 (Using homologous recombination) appears on 2,245 US grants and 5,096 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,245
- Published applications
- 5,096
- Assignees
- 1,364
- Inventors
- 7,457
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 3 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 12 | 0 |
| 1997 | 10 | 0 |
| 1998 | 15 | 0 |
| 1999 | 21 | 0 |
| 2000 | 21 | 0 |
| 2001 | 20 | 1 |
| 2002 | 16 | 39 |
| 2003 | 23 | 44 |
| 2004 | 17 | 53 |
| 2005 | 10 | 41 |
| 2006 | 14 | 42 |
| 2007 | 18 | 21 |
| 2008 | 14 | 25 |
| 2009 | 10 | 38 |
| 2010 | 8 | 28 |
| 2011 | 21 | 51 |
| 2012 | 24 | 63 |
| 2013 | 34 | 56 |
| 2014 | 42 | 125 |
| 2015 | 38 | 126 |
| 2016 | 78 | 175 |
| 2017 | 75 | 189 |
| 2018 | 89 | 267 |
| 2019 | 129 | 333 |
| 2020 | 191 | 419 |
| 2021 | 174 | 446 |
| 2022 | 236 | 490 |
| 2023 | 216 | 562 |
| 2024 | 207 | 547 |
| 2025 | 273 | 513 |
| 2026 | 180 | 402 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Composition for use in treating dystrophic epidermolysis bullosa6 Oct 2026US 12,751,974 B2Osaka University
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Method for modulating RNA splicing by inducing base mutation at splice site or base substitution in polypyrimidine region6 Oct 2026US 12,753,420 B2Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene29 Sep 2026US 12,747,430 B2Precision BioSciences, Inc.
- Humanized ace2-expressing transgenic mouse susceptible to sars-cov-2 virus infection and method for producing same8 Oct 2026US 2026/0305587 A1Seoul National University R&Db Foundation
- Methods of preventing on-target genotoxicity induced by nucleases8 Oct 2026US 2026/0306552 A1Chu De Bordeaux
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
- Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene8 Oct 2026US 2026/0308549 A1Precision BioSciences, Inc.
- Modified guide rnas8 Oct 2026US 2026/0308577 A1Genentech, Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- CRISPR-Cas systems and methods for altering expression of gene products1,186US 8,697,359 B1Massachusetts Institute of Technology · 2014